Category: Business

February 10, 2022 Off

AstraZeneca reports $37,417M revenue; 10% driven by COVID-19 vaccine

By Dino Mustafić

AstraZeneca has reported increase of revenue of 41% (38 at CER) to $37,417 million in results for Q4 and full year 2021 released on Thursday. This includes revenue from  COVID-19 vaccine of $3,981 million. The increase of revenue has been driven by five medicines: Tagrisso ($5bn+), Farxiga ($3bn+), Lynparza ($2bn+), Calquence ($1bn+) and Fasenra ($1bn+).